The Trump administration has shifted course on psychedelic drugs, signing an executive order in April aimed at accelerating research into these compounds for mental illness treatment—a notable reversal from his first term’s harder stance on controlled substances. The administration issued priority review vouchers to three companies: Compass Pathways, Usona Institute, and Transcend Therapeutics, intended to speed up FDA review processes.
Marie Phelan, a U.S. Army Reserve veteran who deployed to Iraq in 2003, underwent MDMA-assisted therapy through clinical trials and credits the experience with transforming her life. “My experience of MDMA was that it just cracked my heart wide open,” she said. “I was carrying this big heavy rucksack and I just put it down on the beach and I started unpacking it one little teeny tiny thing at a time.”
Clinical Evidence and Regulatory Scrutiny
Late-stage trials sponsored by the Multidisciplinary Association for Psychedelic Studies showed roughly 71% of participants with severe PTSD no longer met diagnostic criteria for the disorder after MDMA-assisted therapy sessions. However, the FDA rejected a previous MDMA-assisted therapy application in 2024, citing concerns about the late-stage study design and the need for additional data.
Brandon Weiss, a researcher at Johns Hopkins University School of Medicine’s Center for Psychedelic and Consciousness Research, emphasized that psychedelic compounds carry different safety profiles and risks. Ibogaine, a psychoactive compound derived from a West African shrub referenced in the executive order, has not undergone large-scale clinical trials in the United States and has been linked to potentially serious cardiovascular side effects. “My biggest concern would be that FDA standards are relaxed for politically motivated reasons,” Weiss said, stressing the need for objective interpretation of risks and benefits.
Military Interest and Political Timing
Australia became the first country to allow authorized psychiatrists to prescribe MDMA and psilocybin for certain mental health conditions in 2023. Juliana Mercer, a U.S. Marine Corps veteran and executive director of nonprofit Healing Breakthrough, said the administration’s order “completely changed” her life and represents validation for patients seeking alternative treatments.
Critics have noted the order’s timing amid broader questioning about prioritization of veterans’ care. Phelan rejected the idea that backing psychedelic therapies will translate into political support, noting: “They’d made so many cuts to veteran benefits and medical services. Great, you did a good thing. You did a right thing.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.nytimesnewstoday.com/why-trump-reversed-course-to-fast-track-psychedelic-drugs-for-mental-healthcare/